false
OasisLMS
Catalog
CHEST 2023 On Demand Pass
What's New in Non-CF Bronchiectasis and NTM Lung D ...
What's New in Non-CF Bronchiectasis and NTM Lung Disease - A World Bronchiectasis Session
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Dr. PJ McShane from the University of Texas and Dr. Chuck Daly from National Jewish presented on some of the latest developments in non-CF bronchiolitis and NTM lung disease. Dr. McShane discussed the US bronchiolitis and NTM research registry, which is a centralized database of adult patients with bronchiolitis and NTM lung disease. The registry aims to support collaborative research and assist in planning multicenter clinical trials for these conditions. He highlighted that the registry has been successful in enrolling patients and has resulted in a number of publications. Dr. Daly then discussed innovative therapies for NTM infections. He mentioned that dual beta-lactam therapy has shown promise, especially for the treatment of mycobacterium abscesses. He also discussed several drugs in development for NTM infections, including antibiotics such as epathroboral, ematocycline, and SPR-720. Dr. Daly also mentioned non-antimicrobial approaches such as inhaled nitric oxide, inhaled GM-CSF, and phage therapy. He highlighted the potential benefits of these therapies and stressed the need for more research in these areas. Overall, the presentations highlighted the progress being made in understanding and treating non-CF bronchiolitis and NTM lung disease.
Meta Tag
Category
Chest Infections
Session ID
2155
Speaker
Timothy Aksamit
Speaker
Ashwin Basavaraj
Speaker
James Chalmers
Speaker
Charles Daley
Speaker
Lucy Morgan
Track
Chest Infections
Keywords
non-CF bronchiolitis
NTM lung disease
research registry
multicenter clinical trials
dual beta-lactam therapy
mycobacterium abscesses
epathroboral
ematocycline
SPR-720
×
Please select your language
1
English